Edition:
United States

Oncopeptides AB (ONCO.ST)

ONCO.ST on Stockholm Stock Exchange

88.50SEK
14 Dec 2017
Change (% chg)

0.25kr (+0.28%)
Prev Close
88.25kr
Open
88.25kr
Day's High
90.25kr
Day's Low
87.00kr
Volume
25,684
Avg. Vol
43,412
52-wk High
96.00kr
52-wk Low
41.10kr

Summary

Name Age Since Current Position

Alan Hulme

66 2010 Chairman of the Board

Jakob Lindberg

45 2011 Chief Executive Officer

Birgitta Stahl

46 2016 Chief Financial Officer

Eva Nordstrom

47 2012 Vice President, Head of Clinical Development

Paula Boultbee

59 2016 Chief Commercial Officer

Rein Piir

59 2016 Investor Relations Manager

Elisabeth Augustsson

52 2015 Head of Regulatory Affairs

Johan Harmenberg

63 2012 Chief Medical Officer

Fredrik Lehmann

41 2010 Head of Chemistry, Manufacturing & Control (CMC)

Jonas Brambeck

59 2008 Director

Per Samuelsson

56 2012 Director

Luigi Costa

52 2016 Independent Director

Jarl Jungnelius

66 2011 Independent Director

Olof Tyden

70 2014 Independent Director

Cecilia Wennborg

54 2017 Independent Director

Biographies

Name Description

Alan Hulme

Mr. Alan Hulme has been Chairman of the Board of Directors of Oncopeptides AB since April 2010. In addition, Alan works across Europe with other development stage client companies in the life sciences sector, providing corporate development consultancy services through TechGen International Ltd, London. Previous positions Alan has held have include various senior executive/officer level positions in a number of NYSE and NASDAQ listed life sciences companies in the US as well as two European companies. Alan has also co-founded a venture backed start up. Alan has been located for extensive periods in Asia, the US (East Coast, West Coast and mid-West) and with secondments to Europe, including the UK, Germany, France and Norway. He is Director of Oncopeptides Incentive AB, Techgen Corporate Development Ltd and Techgen International Ltd.

Jakob Lindberg

Dr. Jakob Lindberg, M.D. has been Chief Executive Officer (CEO) of Oncopeptides AB since 2011. Jakob is a Venture Partner at Patricia Industries, part of the Investor AB group of companies. Jakob’s previous roles include being an analyst for Merrill Lynch & Co and a consultant at McKinsey&Co. Jakob also co-founded Cellectricon, a provider of cell-based screening services to accelerate drug discovery, where he also served as CEO. Jakob studied medicine at the Karolinska Institute where he also gained a Med Lic in Molecular Immunology and a MSc in pre-clinical medicine. He also has a BA in Finance and Administration from Stockholm University. He is Director of Affibody Medical AB, Alligator Bioscience AB, Atlas Antibodies AB, Dipylon Medical AB, Lindberg Life-Science AB and Bostadsrattsforeningen Astraea. He also serves as Alternate Director of Oncopeptides Incentive AB and CEO of Lindberg Life-Science AB.

Birgitta Stahl

Ms. Birgitta Stahl has been Chief Financial Officer at Oncopeptides AB since 2016. Previous positions Birgitta has held include COO and acting CFO at Akinion Pharmaceuticals AB and KDev Oncology AB and Vice President Company Operations at Axelar AB, a Swedish drug development company in the field of oncology. Birgitta holds a Master of Science Pharm from Uppsala University and an MBA from University of Westminster in London.

Eva Nordstrom

Ms. Eva Nordstrom has served as Vice President, Head of Clinical Development at Oncopeptides AB since 2012. Previous positions Eva has held include Global Product Director and Vice President roles at Pharmacia and AstraZeneca based both in Sweden and the USA. She has led international cross-functional teams through all phases of drug development and has been responsible for individual project strategies including their implementation as well as disease area strategies, portfolio management and in-licensing. Eva holds a MSc Pharm from Uppsala University and an Executive MBA from Stockholm School of Economics. She is Alternate Director of Utilica AB.

Paula Boultbee

Ms. Paula S. Boultbee has been Chief Commercial Officer at Oncopeptides AB since 2016. Paula is also a principal at PTB Consulting LLC. Paula has held a number of roles in life sciences marketing and has experience in the commercialization of oncology products, including strategic planning and branding. She is currently Chairman at The Max Foundation, which provides support to people living with cancer. In addition, Paula was previously a director at Isofol AB, a Swedish life sciences business. She is Adviser to Monocl AB. Paula trained as a nurse at the Malardalen University in Sweden.

Rein Piir

Mr. Rein Piir has been Investor Relations Manager at Oncopeptides AB since 2016. Rein holds investor relations positions at the life sciences companies Camurus AB and Alligator AB. Previous roles Rein has held include Head of Strategy at Alecta AB and Head of Analysis at Carnegie Investment Bank AB as well as Chief Financial Officer and Head of Investor Relations at Medivir AB. Rein also worked for several years at the international accounting firm PricewaterhouseCoopers. Rein currently holds directorships including at the Swedish life sciences company Integrative Research Laboratories Sweden. Rein Piir holds a B.Sc. Business Economics and Management from Uppsala University, Sweden. He serves as Chairman and CEO of Piir & Partner AB, Director of Integrative Research Laboratories Holding AB, Integrative Research Laboratories Sweden AB, L. E. Svensson Snickeri AB and Trygga Pengar i Mobilen Sverige AB. He is also Vice President Investor Relations at Camurus AB.

Elisabeth Augustsson

Ms. Elisabeth Augustsson has been Head of Regulatory Affairs at Oncopeptides AB since 2015. Elisabeth is the President and Founder of Restracom AB, which provides consulting services to pharmaceutical companies in the area of regulatory strategies and communication. Elisabeth has previously held roles at a number of life sciences companies including Pharmacia&Upjohn, Medivir AB, Biovitrum AB, Karo Bio AB and Alexion AB. Elisabeth holds a MSc Pharm from Uppsala University. She is also Chairman of the Board and CEO of Restracom AB.

Johan Harmenberg

Dr. Johan Harmenberg, M.D., Ph.D. has served as Chief Medical Officer of Oncopeptides AB since 2012. Johan has previously held roles at a number of life sciences companies including as CEO for Axelar AB and Akinion AB, Chief Medical Officer at Algeta AB, Vice President Development for Medivir AB and Global Medical Director for Pharmacia Upjohn. He is the author of over 100 publications for a range of scientific journals. Johan holds a Ph.D. and M.D. from the Karolinska Institute in Stockholm, Sweden. He is also Associate Professor (Docent) at the same institution. He is Chairman of Gungner Medical AB, KarSar Fastigheter AB and Sarak Fastigheter AB as well as Director of Medivir AB and Chief Medical Officer of Glionova AB.

Fredrik Lehmann

Dr. Fredrik Lehmann, Ph.D. has served as Head of Chemistry, Manufacturing & Control (CMC) at Oncopeptides AB since 2010. Fredrik is General Manager Recipharm OT Chemistry AB, a global Contract Development and Manufacturing Organization (CDMO). Fredrik has previously held positions at a number of life sciences businesses including Pharmacia, Personal Chemistry and Biovitrum and has worked as an independent CMC consultant. He has also co-founded six life science companies. Fredrik holds a Ph.D. in medicinal chemistry from Gothenburg University. He is Director and CEO of OncoTargeting Cancer AB and OT Pharmaceuticals AB as well as Board member of OT Lehmann Holding AB and Synartro AB.

Jonas Brambeck

Dr. Jonas Brambeck has been Director of Oncopeptides AB since 2008. In addition to being a board member of Oncopeptides, Jonas is an Investment Manager at Industrifonden, a leading Nordic venture capital fund, and a member of the Board of Directors of the life sciences companies Oxthera AB, Cardoz AB and Nuevolution AS. He is also Board Member of Athera Biotechnologies AB, CMC Contrast AB and OxThera Intellectual Property AB. He has previously held positions at a number of life sciences businesses including AstraZeneca, Bruker Instruments and Nobel. Jonas holds a Ph.D. in organic chemistry from The Royal Institute of Technology in Stockholm.

Per Samuelsson

Mr. Per Samuelsson has been Director of Oncopeptides AB since 2012. Per is a partner at HealthCap, a life sciences venture capital business. Per has over 15 years investment banking experience, mainly with Aros Securities based in Sweden. At Aros Securities he held a number of roles including being a Director in the corporate finance department where he specialized in merger transactions, initial public offerings and equity incentive programs. Per also held the role of Head of Research at Aros Securities. Per holds a Master of Science in Engineering from the Institute of Technology in Linkoping, Sweden. He serves as Director of Ancilla AB, Cantando AB, HealthCap AB, HealthCap Aero Holdings GP AB, HealthCap Annex Fund I-II Bis GP AB, HealthCap Annex Fund I-II GP AB, Health-Cap Holdings GP AB, HealthCap Orx Holdings GP AB, HealthCap 1999 GP AB, HealthCap III Sidefund GP AB, HealthCap IV GP AB, Kip Jansson Film 1 AB, NVC Holding AB, RSPR Incentive AB, RSPR Pharma AB, SwedenBIO Service AB, Nordic Nanovector ASA and Targovax ASA.

Luigi Costa

Mr. Luigi Costa has been Independent Director at Oncopeptides AB since 2016. Luigi has over 20 years of experience in the international pharmaceutical and biotech industries. In addition to being a board member of Oncopeptide, Luigi is the CEO of Nordic Nanovector ASA, a public biotech company focusing on the development and commercialization of novel targeted therapeutics in hematology and oncology. Luigi’s previous positions include Vice President of Europe, Middle East and Africa for Onyx Pharmaceuticals where he led the company’s international organization and the prelaunch and launch of its multiple myeloma drug, Kyprolis in markets outside the USA. Prior to joining Onyx Pharmaceuticals, Luigi held several leadership positions with Amgen, including Head of International Oncology Fanchise, General Manager of Amgen Italy and President of Amgen France, the company’s largest market outside the USA. He has also held various leadership positions with Eli Lilly both in Europe and America. Luigi holds a BSc in Business Administration from the University of Parma and an MBA from Bocconi Business School in Milan.

Jarl Jungnelius

Mr. Jarl Ulf Jungnelius has been Independent Director at Oncopeptides AB since April 2011. Ulf is a licensed medical practitioner and a specialist in a number of areas including oncology. He has published a number of scientific articles and has more than 25 years’ experience in leadership positions in both large academic and corporate institutions. He has been instrumental in the development and registration of gemcitabine (Gemzar), premetrexed (Alimta), Sunitinib (Sutent), lenalidomide (Revlimid) and the albumin bound nanoparticle paclitaxel (Abraxane). He is Director Biovica International AB, Isofol Medical AB, Monocl AB, Noxxon AG and HealthCom GmbH. He holds M.D. and Ph.D. degrees.

Olof Tyden

Prof. Olof Tyden has been Independent Director at Oncopeptides AB since 2014. Olof is a Partner at Eureda, an international pharmaceutical consulting firm. Olof has previously held positions as Medical Director at Leo Pharmaceuticals and Kabi-Vitrum (now Pfizer) and Program Director at the Medical Products Agency in Sweden. Olaf was for six years Senior Regulatory Adviser at Hoffman-La Roche with responsibility for EU strategies, knowledge management and training. In 2000 he founded Eureda, a strategic regulatory consultancy. Olof has also served as an expert to the European Commission in Health Telematics and has been a member of the board of life sciences companies Bioxell SpA, Aprea AB, Cantargia AB and Ximmune AB. Olof holds a Ph.D. from Uppsala University and an associate professorship in obstetrics and gynecology at Uppsala University. He is Director of Eureda AB and Alternate Director of Uppsala Medical Information AB.

Cecilia Wennborg

Ms. Cecilia Daun Wennborg has been Independent Director at Oncopeptides AB since 2017. Cecilia has 14 years of experience from board positions in listed companies. 20 years of experience from operational positions in the insurance, bank and care and healthcare sectors, inter alia as CFO and CEO of Skandia Link, head of Skandia Sverige, CFO of Carema Vard & Omsorg AB and Ambea AB, CEO of Carema Vard & Omsorg AB and deputy CEO of Ambea AB. She was also ordinary member and chairman of the board of directors in Randstad AB (previously Proffice Aktiebolag), board member in Carnegie Fonder AB, Eniro AB, Ikano Bank AB (publ), Aktiebolaget Svensk Bilprovning and Kvinvest AB. Cecilia holds a Master of Science in Business and Economics from Stockholm University. She is Member of the board of directors in Getinge AB, Bravida Holding AB, ICA Gruppen AB, Loomis AB, Atvexa AB, Insamlingsstiftelsen Oxfam Sverige, Sophiahemmet AB and the non-profit organization Sophiahemmet, Hotel Diplomat AB and CDW Konsult AB. She is also Deputy board member in Johan Wennborg Marketing AB.